Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability
- PMID: 30804745
- PMCID: PMC6378854
- DOI: 10.3389/fnins.2019.00086
Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability
Abstract
Oxidative status may play a role in chronic inflammation and neurodegeneration which are considered critical etiopathogenetic factors in Multiple Sclerosis (MS), both in the early phase of the disease and in the progressive one. The aim of this study is to explore oxidative status related to iron metabolism in peripheral blood of stable Relapsing-Remitting MS with low disability. We studied 60 Relapsing-Remitting MS patients (age 37.2 ± 9.06, EDSS median 1.0), and 40 healthy controls (age 40.3 ± 10.86). We measured total hydroperoxides (dROMs test) and Total Antioxidant Status (TAS), along with the iron metabolism biomarkers: Iron (Fe), ferritin (Ferr), transferrin (Tf), transferrin saturation (Tfsat), and ceruloplasmin (Cp) panel biomarkers [concentration (iCp) and enzymatic activity (eCp), copper (Cu), ceruloplasmin specific activity (eCp:iCp), copper to ceruloplasmin ratio (Cu:Cp), non-ceruloplasmin copper (nCp-Cu)]. We computed also the Cp:Tf ratio as an index of oxidative stress related to iron metabolism. We found lower TAS levels in MS patients than in healthy controls (CTRL) and normal reference level and higher dROMs and Cp:Tf ratio in MS than in healthy controls. Cp and Cu were higher in MS while biomarkers of iron metabolism were not different between patients and controls. Both in controls and MS, dROMs correlated with iCp (CTRL r = 0.821, p < 0.001; MS r = 0.775 p < 0.001) and eCp (CTRL r = 0.734, p < 0.001; MS r = 0.820 p < 0.001). Moreover, only in MS group iCp correlated negatively with Tfsat (r = -0.257, p = 0.047). Dividing MS patients in "untreated" group and "treated" group, we found a significant difference in Fe values [F(2, 97) = 10.136, p < 0.001]; in particular "MS untreated" showed higher mean values (mean = 114.5, SD = 39.37 μg/dL) than CTRL (mean 78.6, SD = 27.55 μg/dL p = 0.001) and "MS treated" (mean = 72.4, SD = 38.08 μg/dL; p < 0.001). Moreover, "MS untreated" showed significantly higher values of Cp:Tf (mean = 10.19, SD = 1.77∗10-2; p = 0.015), than CTRL (mean = 9.03, SD = 1.46 ∗10-2). These results suggest that chronic oxidative stress is relevant also in the remitting phase of the disease in patients with low disability and short disease duration. Therefore, treatment with antioxidants may be beneficial also in the early stage of the disease to preserve neuronal reserve.
Keywords: ceruloplasmin; ceruloplasmin:transferrin ratio; hydroperoxides; iron metabolism; multiple sclerosis; oxidative stress; total antioxidant status.
Figures



Similar articles
-
An exploratory study of BDNF and oxidative stress marker alterations in subacute and chronic stroke patients affected by neuropathic pain.J Neural Transm (Vienna). 2017 Dec;124(12):1557-1566. doi: 10.1007/s00702-017-1805-9. Epub 2017 Oct 30. J Neural Transm (Vienna). 2017. PMID: 29086097
-
Inflammation and iron metabolism in adult patients with epilepsy: does a link exist?Epilepsy Res. 2013 Dec;107(3):244-52. doi: 10.1016/j.eplepsyres.2013.09.010. Epub 2013 Sep 28. Epilepsy Res. 2013. PMID: 24128993
-
Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients.Mult Scler. 2005 Jun;11(3):272-5. doi: 10.1191/1352458505ms1171oa. Mult Scler. 2005. PMID: 15957506
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
Does Ceruloplasmin Defend Against Neurodegenerative Diseases?Curr Neuropharmacol. 2019;17(6):539-549. doi: 10.2174/1570159X16666180508113025. Curr Neuropharmacol. 2019. PMID: 29737252 Free PMC article. Review.
Cited by
-
Molecular Biomarkers in Multiple Sclerosis and Its Related Disorders: A Critical Review.Int J Mol Sci. 2020 Aug 21;21(17):6020. doi: 10.3390/ijms21176020. Int J Mol Sci. 2020. PMID: 32825639 Free PMC article. Review.
-
No Vitamin D Deficiency in Patients with Parkinson's Disease.Degener Neurol Neuromuscul Dis. 2022 Sep 26;12:127-131. doi: 10.2147/DNND.S362511. eCollection 2022. Degener Neurol Neuromuscul Dis. 2022. PMID: 36189178 Free PMC article.
-
Plasma Protein Levels Analysis in Multiple Sclerosis Sardinian Families Identified C9 and CYP24A1 as Candidate Biomarkers.Life (Basel). 2022 Jan 20;12(2):151. doi: 10.3390/life12020151. Life (Basel). 2022. PMID: 35207439 Free PMC article.
-
Iron metabolism disorder and multiple sclerosis: a comprehensive analysis.Front Immunol. 2024 Mar 21;15:1376838. doi: 10.3389/fimmu.2024.1376838. eCollection 2024. Front Immunol. 2024. PMID: 38590521 Free PMC article.
-
Superoxide dismutase (SOD), advanced oxidation protein products (AOPP), and disease-modifying treatment are related to better relapse recovery after corticosteroid treatment in multiple sclerosis.Neurol Sci. 2021 Aug;42(8):3241-3247. doi: 10.1007/s10072-020-04928-y. Epub 2020 Nov 26. Neurol Sci. 2021. PMID: 33241537
References
-
- Abe A., Yamashita S., Noma A. (1989). Sensitive, direct colorimetric assay for copper in serum. Clin. Chem. 35 552–554. - PubMed
-
- Alberti A., Bolognini L., Macciantelli D., Caratelli M. (2000). The radical cation of N,N-Diethyl-para-phenylendiamine: a possible indicator of oxidative stress in biological samples. Res. Chem. Intermed. 26 253–267. 10.1163/156856700X00769 - DOI
LinkOut - more resources
Full Text Sources
Miscellaneous